JP2022141773A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022141773A5 JP2022141773A5 JP2022111844A JP2022111844A JP2022141773A5 JP 2022141773 A5 JP2022141773 A5 JP 2022141773A5 JP 2022111844 A JP2022111844 A JP 2022111844A JP 2022111844 A JP2022111844 A JP 2022111844A JP 2022141773 A5 JP2022141773 A5 JP 2022141773A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- carbocyclyl
- pharmaceutically acceptable
- compound
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000004452 carbocyclyl group Chemical group 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 208000014644 Brain disease Diseases 0.000 claims 2
- 208000032274 Encephalopathy Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 230000001037 epileptic effect Effects 0.000 claims 2
- 201000007547 Dravet syndrome Diseases 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 1
- 208000035899 Infantile spasms syndrome Diseases 0.000 claims 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024084718A JP2024100974A (ja) | 2016-11-28 | 2024-05-24 | 化合物及びその使用方法 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662427044P | 2016-11-28 | 2016-11-28 | |
| US62/427,044 | 2016-11-28 | ||
| US201762458306P | 2017-02-13 | 2017-02-13 | |
| US62/458,306 | 2017-02-13 | ||
| US201762552073P | 2017-08-30 | 2017-08-30 | |
| US62/552,073 | 2017-08-30 | ||
| JP2019548536A JP7105797B2 (ja) | 2016-11-28 | 2017-11-28 | 化合物及びその使用方法 |
| PCT/US2017/063533 WO2018098499A1 (en) | 2016-11-28 | 2017-11-28 | Compounds and their methods of use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548536A Division JP7105797B2 (ja) | 2016-11-28 | 2017-11-28 | 化合物及びその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024084718A Division JP2024100974A (ja) | 2016-11-28 | 2024-05-24 | 化合物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022141773A JP2022141773A (ja) | 2022-09-29 |
| JP2022141773A5 true JP2022141773A5 (enExample) | 2023-06-20 |
| JP7495962B2 JP7495962B2 (ja) | 2024-06-05 |
Family
ID=62195384
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548536A Active JP7105797B2 (ja) | 2016-11-28 | 2017-11-28 | 化合物及びその使用方法 |
| JP2022111844A Active JP7495962B2 (ja) | 2016-11-28 | 2022-07-12 | 化合物及びその使用方法 |
| JP2024084718A Pending JP2024100974A (ja) | 2016-11-28 | 2024-05-24 | 化合物及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548536A Active JP7105797B2 (ja) | 2016-11-28 | 2017-11-28 | 化合物及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024084718A Pending JP2024100974A (ja) | 2016-11-28 | 2024-05-24 | 化合物及びその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11629146B2 (enExample) |
| EP (2) | EP3548033B1 (enExample) |
| JP (3) | JP7105797B2 (enExample) |
| CN (2) | CN116763791A (enExample) |
| AU (3) | AU2017364901A1 (enExample) |
| BR (1) | BR112019010880A2 (enExample) |
| DK (1) | DK3548033T3 (enExample) |
| ES (1) | ES2992063T3 (enExample) |
| FI (1) | FI3548033T3 (enExample) |
| HU (1) | HUE068842T2 (enExample) |
| PL (1) | PL3548033T3 (enExample) |
| PT (1) | PT3548033T (enExample) |
| WO (1) | WO2018098499A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3548033B1 (en) | 2016-11-28 | 2024-04-10 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018098491A1 (en) | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11731966B2 (en) | 2017-04-04 | 2023-08-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| CN119350320A (zh) * | 2018-05-30 | 2025-01-24 | 普拉克西斯精密药物股份有限公司 | 离子通道调节剂 |
| EA202190581A1 (ru) | 2018-08-20 | 2021-07-13 | Рогкон, Инк. | Антисмысловые олигонуклеотиды, нацеленные на scn2a, для лечения энцефалопатии scn1a |
| EA202092908A1 (ru) * | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| WO2021039961A1 (ja) * | 2019-08-30 | 2021-03-04 | 大日本住友製薬株式会社 | 縮環ピラゾール誘導体 |
| KR20220119624A (ko) | 2019-11-26 | 2022-08-30 | 프락시스 프리시젼 메디신즈, 인크. | 이온 채널 조절제 |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| US20230348466A1 (en) * | 2019-11-27 | 2023-11-02 | Praxis Precision Medicines, Inc. | Formulations of ion channel modulators and methods of preparation and use of ion channel modulators |
| JP2021195367A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| PE20242111A1 (es) * | 2021-09-13 | 2024-10-28 | Boehringer Ingelheim Vetmedica Gmbh | Derivados de etilsulfonil-piridina sustituidos con ciclopropil-(hetero)arilo |
| CA3250706A1 (en) * | 2022-04-26 | 2023-11-02 | Praxis Precision Medicines, Inc. | TREATMENT OF NEUROLOGICAL DISORDERS |
| WO2024077273A2 (en) * | 2022-10-07 | 2024-04-11 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| CA1080712A (en) | 1976-09-22 | 1980-07-01 | Jay D. Albright | Hypotensive agents |
| US4230705A (en) * | 1976-09-22 | 1980-10-28 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety |
| US4112095A (en) * | 1976-10-07 | 1978-09-05 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents |
| US4242515A (en) | 1979-03-28 | 1980-12-30 | American Cyanamid Company | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| GB9507348D0 (en) * | 1995-04-08 | 1995-05-31 | Knoll Ag | Therapeutic agents |
| CA2419626A1 (en) | 2000-07-14 | 2002-01-24 | Rajagopal Bakthavatachalam | Imidazo¬1,2-a|pyrazines for the treatment of neurological disorders |
| AU2004251647B2 (en) * | 2003-05-29 | 2010-01-14 | Takeda Pharmaceutical Company Limited | Abuse resistant amphetamine compounds |
| US7645756B2 (en) * | 2004-02-18 | 2010-01-12 | Banyu Pharmaceutical Co. Ltd. | Nitrogenous fused heteroaromatic ring derivative |
| WO2006061428A2 (en) | 2004-12-10 | 2006-06-15 | Universität Zürich | Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain |
| CA2612180A1 (en) | 2005-06-16 | 2006-12-21 | Bionomics Limited | Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene |
| EP1966214B9 (en) | 2005-12-21 | 2017-09-13 | Janssen Pharmaceutica N.V. | Triazolopyridazines as tyrosine kinase modulators |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| FR2915198B1 (fr) | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| EA201070914A1 (ru) | 2008-02-06 | 2011-04-29 | Гайлид Сайэнсиз, Инк. | Применение ранолазина для лечения боли |
| WO2010053757A1 (en) | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| WO2010074807A1 (en) | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
| WO2010056865A1 (en) | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Quinoline derivatives as ion channel modulators |
| TWI469979B (zh) | 2008-12-24 | 2015-01-21 | Bial Portela & Ca Sa | 脂肪酸醯胺水解酶(faah)抑制劑、以及其藥學組成物與用途 |
| JP5340798B2 (ja) | 2009-05-07 | 2013-11-13 | タイガースポリマー株式会社 | 地中埋設管の製造方法 |
| EA020672B1 (ru) | 2009-05-12 | 2014-12-30 | Янссен Фармасьютикалс, Инк. | Производные 1,2,4-триазоло[4,3-a]пиридина и их применение для лечения или предупреждения неврологических и психиатрических расстройств |
| US8952034B2 (en) | 2009-07-27 | 2015-02-10 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2011056985A2 (en) | 2009-11-04 | 2011-05-12 | Gilead Sciences, Inc. | Substituted heterocyclic compounds |
| FR2953520B1 (fr) | 2009-12-04 | 2011-11-25 | Sanofi Aventis | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique |
| WO2012003338A1 (en) | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| EA026385B9 (ru) | 2010-07-02 | 2017-08-31 | Джилид Сайэнс, Инк. | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов |
| WO2012065297A1 (en) | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| WO2012151136A1 (en) | 2011-05-03 | 2012-11-08 | Merck Sharp & Dohme Corp. | Aminomethyl biaryl benzotriazole derivatives |
| CN105693645B (zh) | 2011-05-10 | 2018-10-09 | 吉利德科学公司 | 作为离子通道调节剂的稠合杂环化合物 |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| WO2013043925A1 (en) | 2011-09-21 | 2013-03-28 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| EP2760866B1 (en) | 2011-09-27 | 2017-12-13 | Genfit | Derivatives of 6-substituted triazolopyridazines as rev-erb agonists |
| CN103122000B (zh) * | 2012-09-03 | 2013-12-25 | 中美冠科生物技术（太仓）有限公司 | 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂 |
| TWI574962B (zh) * | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途 |
| US20150344457A1 (en) | 2012-12-21 | 2015-12-03 | Epizyme, Inc. | Methods of inhibiting prmt5 |
| WO2014179492A1 (en) | 2013-05-01 | 2014-11-06 | Gilead Sciences, Inc. | Combination therapy for the treatment of arrhythmias or heart failure |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| PT3035926T (pt) | 2013-08-19 | 2020-09-01 | Univ California | Compostos e métodos para tratar um distúrbio epiléptico |
| GB201321740D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| US9416128B2 (en) | 2013-12-19 | 2016-08-16 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2015157955A1 (en) | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| JP2017516836A (ja) * | 2014-06-04 | 2017-06-22 | リューゲン ホールディングス （ケイマン） リミテッド | Ｎｒ２ｂｎｍｄａ受容体アンタゴニストとしてのジフルオロエチルピリジン誘導体 |
| ES2785560T3 (es) | 2014-06-20 | 2020-10-07 | Mitsubishi Chem Corp | Policarbonato diol, método para producir el mismo, y poliuretano producido utilizando el mismo |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| AU2015279377B2 (en) | 2014-06-26 | 2019-09-12 | F. Hoffmann-La Roche Ag | Indolin-2-one or pyrrolo-pyridin-2-one derivatives |
| JP2017001991A (ja) | 2015-06-11 | 2017-01-05 | 大日本住友製薬株式会社 | 新規ベンズオキサゾロン化合物 |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| WO2018098491A1 (en) | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US20210188839A1 (en) | 2016-11-28 | 2021-06-24 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| EP3548033B1 (en) | 2016-11-28 | 2024-04-10 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11731966B2 (en) | 2017-04-04 | 2023-08-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| CN119350320A (zh) | 2018-05-30 | 2025-01-24 | 普拉克西斯精密药物股份有限公司 | 离子通道调节剂 |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| KR20220119624A (ko) | 2019-11-26 | 2022-08-30 | 프락시스 프리시젼 메디신즈, 인크. | 이온 채널 조절제 |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| US20230348466A1 (en) | 2019-11-27 | 2023-11-02 | Praxis Precision Medicines, Inc. | Formulations of ion channel modulators and methods of preparation and use of ion channel modulators |
-
2017
- 2017-11-28 EP EP17874657.4A patent/EP3548033B1/en active Active
- 2017-11-28 AU AU2017364901A patent/AU2017364901A1/en not_active Abandoned
- 2017-11-28 US US16/464,468 patent/US11629146B2/en active Active
- 2017-11-28 WO PCT/US2017/063533 patent/WO2018098499A1/en not_active Ceased
- 2017-11-28 ES ES17874657T patent/ES2992063T3/es active Active
- 2017-11-28 BR BR112019010880A patent/BR112019010880A2/pt unknown
- 2017-11-28 EP EP24160394.3A patent/EP4397308A3/en active Pending
- 2017-11-28 CN CN202310582446.9A patent/CN116763791A/zh active Pending
- 2017-11-28 PL PL17874657.4T patent/PL3548033T3/pl unknown
- 2017-11-28 DK DK17874657.4T patent/DK3548033T3/da active
- 2017-11-28 CN CN201780084790.8A patent/CN110337295B/zh active Active
- 2017-11-28 PT PT178746574T patent/PT3548033T/pt unknown
- 2017-11-28 FI FIEP17874657.4T patent/FI3548033T3/fi active
- 2017-11-28 HU HUE17874657A patent/HUE068842T2/hu unknown
- 2017-11-28 JP JP2019548536A patent/JP7105797B2/ja active Active
-
2022
- 2022-07-12 JP JP2022111844A patent/JP7495962B2/ja active Active
-
2023
- 2023-03-10 US US18/119,963 patent/US20230322790A1/en not_active Abandoned
- 2023-12-14 AU AU2023282271A patent/AU2023282271A1/en not_active Abandoned
-
2024
- 2024-05-24 JP JP2024084718A patent/JP2024100974A/ja active Pending
- 2024-12-06 US US18/971,281 patent/US20250163068A1/en active Pending
-
2025
- 2025-09-23 AU AU2025237912A patent/AU2025237912A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022141773A5 (enExample) | ||
| JP2024100974A5 (enExample) | ||
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| JP2009536620A5 (enExample) | ||
| RU2004126671A (ru) | Гетероарилсоединения, полезные в качестве ингибиторов gsk-3 | |
| JP2012521994A5 (enExample) | ||
| JP2020526561A5 (enExample) | ||
| JP2020502047A5 (enExample) | ||
| JP2011500758A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| JP2010518128A5 (enExample) | ||
| JP2005523922A5 (enExample) | ||
| JP2017504576A5 (enExample) | ||
| JP2018511647A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2013010792A5 (enExample) | ||
| JP2016513663A5 (enExample) | ||
| JP2009524691A5 (enExample) | ||
| JP2020506951A5 (enExample) | ||
| JP2003525850A5 (enExample) | ||
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| JP2005539045A5 (enExample) | ||
| JP2011513410A5 (enExample) | ||
| JP2019527724A5 (enExample) | ||
| JPWO2020006264A5 (enExample) |